These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 15664690)

  • 21. Impairments in impulse control in mice transgenic for the human FTDP-17 tauV337M mutation are exacerbated by age.
    Lambourne SL; Humby T; Isles AR; Emson PC; Spillantini MG; Wilkinson LS
    Hum Mol Genet; 2007 Jul; 16(14):1708-19. PubMed ID: 17517691
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neurodegeneration and Alzheimer's disease: the lesson from tauopathies.
    Sorrentino G; Bonavita V
    Neurol Sci; 2007 Apr; 28(2):63-71. PubMed ID: 17464468
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biomedicine. Tauists and beta-aptists united--well almost!
    Lee VM
    Science; 2001 Aug; 293(5534):1446-7. PubMed ID: 11520974
    [No Abstract]   [Full Text] [Related]  

  • 24. Transgenic mice expressing mutant (N279K) human tau show mutation dependent cognitive deficits without neurofibrillary tangle formation.
    Taniguchi T; Doe N; Matsuyama S; Kitamura Y; Mori H; Saito N; Tanaka C
    FEBS Lett; 2005 Oct; 579(25):5704-12. PubMed ID: 16219306
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FTDP-17 mutations in tau transgenic mice provoke lysosomal abnormalities and Tau filaments in forebrain.
    Lim F; Hernández F; Lucas JJ; Gómez-Ramos P; Morán MA; Avila J
    Mol Cell Neurosci; 2001 Dec; 18(6):702-14. PubMed ID: 11749044
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Formation of filamentous tau aggregations in transgenic mice expressing V337M human tau.
    Tanemura K; Akagi T; Murayama M; Kikuchi N; Murayama O; Hashikawa T; Yoshiike Y; Park JM; Matsuda K; Nakao S; Sun X; Sato S; Yamaguchi H; Takashima A
    Neurobiol Dis; 2001 Dec; 8(6):1036-45. PubMed ID: 11741399
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alzheimer's disease. A new take on tau.
    Marx J
    Science; 2007 Jun; 316(5830):1416-7. PubMed ID: 17556561
    [No Abstract]   [Full Text] [Related]  

  • 28. Alzheimer's disease: beta-Amyloid protein and tau.
    Morishima-Kawashima M; Ihara Y
    J Neurosci Res; 2002 Nov; 70(3):392-401. PubMed ID: 12391602
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Filamin-A and Myosin VI colocalize with fibrillary Tau protein in Alzheimer's disease and FTDP-17 brains.
    Feuillette S; Deramecourt V; Laquerriere A; Duyckaerts C; Delisle MB; Maurage CA; Blum D; Buée L; Frébourg T; Campion D; Lecourtois M
    Brain Res; 2010 Jul; 1345():182-9. PubMed ID: 20460118
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Parallel increase in p70 kinase activation and tau phosphorylation (S262) with Abeta overproduction.
    Zhou XW; Tanila H; Pei JJ
    FEBS Lett; 2008 Jan; 582(2):159-64. PubMed ID: 18068129
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Frontotemporal dementia with tau pathology.
    Gasparini L; Terni B; Spillantini MG
    Neurodegener Dis; 2007; 4(2-3):236-53. PubMed ID: 17596718
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Altered distribution of RhoA in Alzheimer's disease and AbetaPP overexpressing mice.
    Huesa G; Baltrons MA; Gómez-Ramos P; Morán A; García A; Hidalgo J; Francés S; Santpere G; Ferrer I; Galea E
    J Alzheimers Dis; 2010; 19(1):37-56. PubMed ID: 20061625
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mechanisms of memory loss in Abeta and tau mouse models.
    Ashe KH
    Biochem Soc Trans; 2005 Aug; 33(Pt 4):591-4. PubMed ID: 16042551
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A highly insoluble state of Abeta similar to that of Alzheimer's disease brain is found in Arctic APP transgenic mice.
    Philipson O; Hammarström P; Nilsson KP; Portelius E; Olofsson T; Ingelsson M; Hyman BT; Blennow K; Lannfelt L; Kalimo H; Nilsson LN
    Neurobiol Aging; 2009 Sep; 30(9):1393-405. PubMed ID: 18192084
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modulation of tau pathology in tau transgenic models.
    Brion JP; Ando K; Heraud C; Leroy K
    Biochem Soc Trans; 2010 Aug; 38(4):996-1000. PubMed ID: 20658992
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Divergent phosphorylation pattern of tau in P301L tau transgenic mice.
    Deters N; Ittner LM; Götz J
    Eur J Neurosci; 2008 Jul; 28(1):137-47. PubMed ID: 18662339
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits.
    Schindowski K; Bretteville A; Leroy K; Bégard S; Brion JP; Hamdane M; Buée L
    Am J Pathol; 2006 Aug; 169(2):599-616. PubMed ID: 16877359
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Molecular analysis of tau deposited in the FTDP-17 brain].
    Morishima-Kawashima M
    Rinsho Shinkeigaku; 2001 Dec; 41(12):1107-10. PubMed ID: 12235810
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of the cholinergic pathology in the P301L tau transgenic pR5 model of tauopathy.
    Köhler C; Bista P; Götz J; Schröder H
    Brain Res; 2010 Aug; 1347():111-24. PubMed ID: 20513372
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Neurofibrillary tangles and early modification of the neuronal cytoskeleton in Alzheimer's disease and in experimental models].
    Brion JP
    Bull Mem Acad R Med Belg; 1999; 154(6 Pt 2):287-94. PubMed ID: 10992876
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.